Panelist: Lionel Bascles SVP, Global Head Clinical Sciences & Operation Sanofi
Panelist: Melissa Penn Deputy Director Advocacy Relations Bayer
Panelist: Joy Bhosai Founder and CEO Pluto Health
Panelist: David Coman Chief Executive Officer Science 37
Moderator: Laura Galuchie Director, Global Clinical Trial Operations Merck
The fact that the pandemic necessitated and drove the adoption of Decentralized Clinical Trial (DCT) approaches is old news. We’ve all seen it happen, and we all by now know it’s started an unstoppable momentum toward a different clinical development future – a patient-centred future.
Now we’re faced with a new set of challenges to overcome to make this momentum reality now.
Most biopharma companies plan to integrate DCT tools and methods even further into their clinical trials—but the majority lack the internal capabilities to do so. We need a consistent, technology-led approach that can gather patient preferences fast enough to shape trial design in real-time and optimize possibilities for enrolment and retention. It must be agile enough to integrate into traditional trials with brick-and-mortar sites and scalable enough to empower clinical trials in hybrid or virtual format—unbound by geographic limitations.
Join Bayer, Sanofi, Merck, Pluto Health and Science37 as they discuss how to implement a broader, more inclusive approach to study design and conduct. Discover:
*All sign-ups receive a recorded version of the session.